Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173

Summary

In this single-dose, randomized, 5-way cross-over study, healthy volunteers were treated with the highest approved dose of octreotide, three different doses of Somatoprim (DG3173) and placebo control. The main purpose of the study was to investigate the effects of each treatment on the control of plasma glucose as well as the secretion of insulin and glucagon following a standard meal.

Timeline

Start

—

Primary completion

2014-04

Completion

—

Drugs

Indications

No indication recorded.